In Patients with Coronary Artery Disease and Type 2 Diabetes, SIRT1 Expression in Circulating Mononuclear Cells Is Associated with Levels of Inflammatory Cytokines but Not with Coronary Lesions

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Li, Yuanmin ^a   Ni, Jing ^a   Guo, Rong ^a   Li, Weiming ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SIRTUIN 1; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DIABETIC PATIENT; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYNTAX SCORE; BLOOD; COMPLICATION; DEMOGRAPHY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MONONUCLEAR CELL;

ADULT; CORONARY ARTERY DISEASE; CYTOKINES; DEMOGRAPHY; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RNA, MESSENGER; SIRTUIN 1;

EID: 84971422217     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/8734827     Document Type: Article

References (43)

1. S. H. Ley, O. Hamdy, V. Mohan, and F. B. Hu, "Prevention and management of type 2 diabetes: dietary components and nutritional strategies, " The Lancet, vol. 383, no. 9933, pp. 1999-2007, 2014.
2. P. S. Baweja, P. B. Sandesara, and M. J. Ashraf, "Asymptomatic coronary artery disease in type II diabetes, " Missouri Medicine, vol. 111, no. 1, pp. 73-79, 2014.
3. M. G. Zeadin, C. I. Petlura, and G. H. Werstuck, "Molecular mechanisms linking diabetes to the accelerated development of atherosclerosis, " Canadian Journal of Diabetes, vol. 37, no. 5, pp. 345-350, 2013.
4. L. H. Young, F. J. T. Wackers, D. A. Chyun et al., "Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes the DIAD study: A randomized controlled trial, " The Journal of the American Medical Association, vol. 301, no. 15, pp. 1547-1555, 2009.
5. E. J. Armstrong, J. Waltenberger, and J. H. Rogers, "Percutaneous coronary intervention in patients with diabetes: current concepts and future directions, " Journal of Diabetes Science and Technology, vol. 8, no. 3, pp. 581-589, 2014.
6. G. R. Myers and W. S. Weintraub, "Coronary artery disease: revascularization strategies for patients with CAD and diabetes, " Nature Reviews Cardiology, vol. 7, no. 7, pp. 364-366, 2010.
7. M. J. Zellweger, M. Maraun, H. H. Osterhues et al., "Progression to overt or silent cad in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a pilot randomized treatment substudy, " JACC: Cardiovascular Imaging, vol. 7, no. 10, pp. 1001-1010, 2014.
8. K. M. Hirahatake, J. L. Slavin, K. C. Maki, and S. H. Adams, "Associations between dairy foods, diabetes, and metabolic health: potential mechanisms and future directions, " Metabolism: Clinical and Experimental, vol. 63, no. 5, pp. 618-627, 2014.
9. M. Quiñones, O. Al-Massadi, J. Fernø, and R. Nogueiras, "Cross-talk between SIRT1 and endocrine factors: effects on energy homeostasis, "Molecular and Cellular Endocrinology, vol. 397, no. 1-2, pp. 42-50, 2014.
10. X. Hou, S. Xu, K. A. Maitland-Toolan et al., "SIRT1 regulates hepatocyte lipidmetabolism through activating AMP-activated protein kinase, " Journal of Biological Chemistry, vol. 283, no. 29, pp. 20015-20026, 2008.
11. M. Kitada and D. Koya, "SIRT1 in type 2 diabetes: mechanisms and therapeutic potential, " Diabetes and Metabolism Journal, vol. 37, no. 5, pp. 315-325, 2013.
12. S. Stein, C. Lohmann, N. Schäfer et al., "SIRT1 decreases Lox-1-mediated foamcell formation in atherogenesis, " EuropeanHeart Journal, vol. 31, no. 18, pp. 2301-2309, 2010.
13. Y. Hu, L. Wang, S. Chen et al., "Association between the SIRT1 mRNA expression and acute coronary syndrome, " Journal of Atherosclerosis and Thrombosis, vol. 22, no. 2, pp. 165-182, 2015.
14. A. Breitenstein, C. A. Wyss, R. D. Spescha et al., "Peripheral blood monocyte sirt1 expression is reduced in patients with coronary artery disease, " PLoS ONE, vol. 8, no. 1, Article ID e53106, 2013.
15. R. Guo, Y. Su, B. Liu, S. Li, S. Zhou, and Y. Xu, "Resveratrol suppresses oxidised low-density lipoprotein-induced macrophage apoptosis through inhibition of intracellular reactive oxygen species generation, LOX-1, and the p38 MAPK pathway, " Cellular Physiology and Biochemistry, vol. 34, no. 2, pp. 603-616, 2014.
16. S. Stein, N. Schäfer, A. Breitenstein et al., "SIRT1 reduces endothelial activation without affecting vascular function inApoE-/-mice, " Aging, vol. 2, no. 6, pp. 353-360, 2010.
17. S. Carter, S. Miard, C. Roy-Bellavance et al., "Sirt1 inhibits resistin expression in aortic stenosis, " PLoS ONE, vol. 7, no. 4, Article ID e35110, 2012.
18. H.-T. Zeng, Y.-C. Fu, W. Yu et al., "SIRT1 prevents atherosclerosis via liver-X-receptor and NF-B signaling in a U937 cell model, " Molecular Medicine Reports, vol. 8, no. 1, pp. 23-28, 2013.
19. American Diabetes Association, "Classification and diagnosis of diabetes, " Diabetes Care, vol. 38, supplement, pp. S8-S16, 2015.
20. SYNTAX Score, http://www. syntaxscore. com.
21. G. Sianos, M. A. Morel, A. P. Kappetein et al., "The SYNTAX Score: An angiographic tool grading the complexity of coronary artery disease, " EuroIntervention, vol. 1, no. 2, pp. 219-227, 2005.
22. L. R. Staimez, M. B. E. Weber, and E. W. Gregg, "The role of lifestyle change for prevention of cardiovascular disease in diabetes, " Current atherosclerosis reports, vol. 16, no. 12, article 460, 2014.
23. R. Guo, B. Liu, K. Wang, S. Zhou, W. Li, and Y. Xu, "Resveratrol ameliorates diabetic vascular inflammation and macrophage infiltration in db/db mice by inhibiting the NF-B pathway, " Diabetes and Vascular Disease Research, vol. 11, no. 2, pp. 92-102, 2014.
24. R. Guo, W. Liu, B. Liu, B. Zhang, W. Li, and Y. Xu, "SIRT1 suppresses cardiomyocyte apoptosis in diabetic cardiomyopathy: An insight into endoplasmic reticulum stress response mechanism, " International Journal of Cardiology, vol. 191, pp. 36-45, 2015.
25. M. Kitada, S. Kume, K. Kanasaki, A. Takeda-Watanabe, and D. Koya, "Sirtuins as possible drug targets in type 2 diabetes, " Current Drug Targets, vol. 14, no. 6, pp. 622-636, 2013.
26. A. B. Crujeiras, D. Parra, E. Goyenechea, and J. A. Martínez, "Sirtuin gene expression in human mononuclear cells is modulated by caloric restriction, " European Journal of Clinical Investigation, vol. 38, no. 9, pp. 672-678, 2008.
27. S. V. de Kreutzenberg, G. Ceolotto, I. Papparella et al., "Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms, " Diabetes, vol. 59, no. 4, pp. 1006-1015, 2010.
28. R. Song, W. Xu, Y. Chen, Z. Li, Y. Zeng, and Y. Fu, "The expression of sirtuins 1 and 4 in peripheral blood leukocytes from patients with type 2 diabetes, " European Journal of Histochemistry, vol. 55, no. 1, article e10, 2011.
29. R. Caruso, I. Marafini, E. Franzè et al., "Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut, " Mucosal Immunology, vol. 7, no. 6, pp. 1467-1479, 2014.
30. G. Ceolotto, S. V. De Kreutzenberg, A. Cattelan et al., "Sirtuin 1 stabilization by HuR represses TNF-and glucose-induced E-selectin release and endothelial cell adhesiveness in vitro: relevance to human metabolic syndrome, " Clinical Science, vol. 127, no. 7, pp. 449-461, 2014.
31. A. Storka, G. Führlinger, M. Seper et al., "E. coli endotoxinmodulates the expression of sirtuin proteins in PBMC in humans, " Mediators of Inflammation, vol. 2013, Article ID876943, 6 pages, 2013.
32. S. Matsushima and J. Sadoshima, "The role of sirtuins in cardiac disease, "American Journal of Physiology-Heart and Circulatory Physiology, vol. 309, no. 9, pp. H1375-H1389, 2015.
33. I. Gorenne, S. Kumar, K. Gray et al., "Vascular smooth muscle cell sirtuin 1 protects against dna damage and inhibits atherosclerosis, " Circulation, vol. 127, no. 3, pp. 386-396, 2013.
34. N. D'Onofrio, M. Vitiello, R. Casale, L. Servillo, A. Giovane, and M. L. Balestrieri, "Sirtuins in vascular diseases: emerging roles and therapeutic potential, " Biochimica et BiophysicaActa-Molecular Basis of Disease, vol. 1852, no. 7, pp. 1311-1322, 2015.
35. S. Kume, T. Uzu, A. Kashiwagi, and D. Koya, "SIRT1, a calorie restriction mimetic, in a new therapeutic approach for type 2 diabetes mellitus and diabetic vascular complications, " Endocrine, Metabolic and Immune Disorders-Drug Targets, vol. 10, no. 1, pp. 16-24, 2010.
36. H.-C. Su, L.-M. Hung, and J.-K. Chen, "Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocininduced diabetic rats, " American Journal of Physiology-Endocrinology andMetabolism, vol. 290, no. 6, pp. E1339-E1346, 2006.
37. M. Lagouge, C. Argmann, Z. Gerhart-Hines et al., "Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 , " Cell, vol. 127, no. 6, pp. 1109-1122, 2006.
38. J. P. Crandall, V. Oram, G. Trandafirescu et al., "Pilot study of resveratrol in older adults with impaired glucose tolerance, " Journals of Gerontology A: Biological Sciences and Medical Sciences, vol. 67, no. 12, pp. 1307-1312, 2012.
39. K. Magyar, R. Halmosi, A. Palfi et al., "Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease, " Clinical Hemorheology and Microcirculation, vol. 50, no. 3, pp. 179-187, 2012.
40. J. C. Milne, P. D. Lambert, S. Schenk et al., "Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes, " Nature, vol. 450, no. 7170, pp. 712-716, 2007.
41. V. Libri, A. P. Brown, G. Gambarota et al., "A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers, " PLoS ONE, vol. 7, no. 12, Article ID e51395, 2012.
42. M. M. Poulsen, P. F. Vestergaard, B. F. Clasen et al., "Highdose resveratrol supplementation in obesemen: An investigatorinitiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition, " Diabetes, vol. 62, no. 4, pp. 1186-1195, 2013.
43. R. D. Semba, L. Ferrucci, B. Bartali et al., "Resveratrol levels and all-causemortality in older community-dwelling adults, " JAMA Internal Medicine, vol. 174, no. 7, pp. 1077-1084, 2014.